T M Seay1, S J Peretsman, P S Dixon. 1. Department of Urology, Wilford Hall Medical Center, Lackland Air Force Base, Texas, USA.
Abstract
PURPOSE: The in vitro effects of the fluoroquinolone antibiotics ciprofloxacin and ofloxacin upon 3 human transitional cell carcinoma cell lines were investigated at concentrations that are attainable in the urine of patients taking these drugs orally. MATERIALS AND METHODS: Cell lines TCCSUP, T24, and J82 were exposed in culture to either ciprofloxacin or ofloxacin at concentrations ranging from 0 to 800 micrograms./ml. and at durations ranging from 24 to 120 hours. Inhibition of proliferation and DNA synthesis were assessed via MTT and tritiated thymidine assays, respectively. RESULTS: From the MTT assay ciprofloxacin, at concentrations of 25 to 800 micrograms./ml., produced proliferation inhibition in the TCCSUP line ranging from 8.1% to 90.2% at 24 hours, 25.1% to 94.9% at 72 hours, and 53.8% to 96.9% at 120 hours. Inhibition of proliferation for the T24 line ranged from 8.0% to 85%, 31.5% to 96.5%, and 27.3% to 98.2%. Inhibition of proliferation of the J82 line ranged from 20.8% to 84.8%, 22.8% to 92.7%, and 37.4% to 97.1%. Inhibition of DNA synthesis (due to ciprofloxacin at the concentrations above) as measured by the tritiated thymidine assay was also significant for each of the 3 cell lines. Inhibition of proliferation and DNA synthesis due to ofloxacin was lower but not overall statistically different from that due to ciprofloxacin. In a separate experiment, enhanced cytotoxicity was observed at lower concentrations of ciprofloxacin when the initial media pH was approximated to 5.5. CONCLUSIONS: Ciprofloxacin and ofloxacin inhibit proliferation and DNA synthesis of these 3 human TCC lines in vitro. Inhibition occurred in a concentration- and time-dependent manner. The concentrations that were assessed are attainable in the urine of patients taking these agents orally.
PURPOSE: The in vitro effects of the fluoroquinolone antibiotics ciprofloxacin and ofloxacin upon 3 human transitional cell carcinoma cell lines were investigated at concentrations that are attainable in the urine of patients taking these drugs orally. MATERIALS AND METHODS: Cell lines TCCSUP, T24, and J82 were exposed in culture to either ciprofloxacin or ofloxacin at concentrations ranging from 0 to 800 micrograms./ml. and at durations ranging from 24 to 120 hours. Inhibition of proliferation and DNA synthesis were assessed via MTT and tritiated thymidine assays, respectively. RESULTS: From the MTT assay ciprofloxacin, at concentrations of 25 to 800 micrograms./ml., produced proliferation inhibition in the TCCSUP line ranging from 8.1% to 90.2% at 24 hours, 25.1% to 94.9% at 72 hours, and 53.8% to 96.9% at 120 hours. Inhibition of proliferation for the T24 line ranged from 8.0% to 85%, 31.5% to 96.5%, and 27.3% to 98.2%. Inhibition of proliferation of the J82 line ranged from 20.8% to 84.8%, 22.8% to 92.7%, and 37.4% to 97.1%. Inhibition of DNA synthesis (due to ciprofloxacin at the concentrations above) as measured by the tritiated thymidine assay was also significant for each of the 3 cell lines. Inhibition of proliferation and DNA synthesis due to ofloxacin was lower but not overall statistically different from that due to ciprofloxacin. In a separate experiment, enhanced cytotoxicity was observed at lower concentrations of ciprofloxacin when the initial media pH was approximated to 5.5. CONCLUSIONS:Ciprofloxacin and ofloxacin inhibit proliferation and DNA synthesis of these 3 human TCC lines in vitro. Inhibition occurred in a concentration- and time-dependent manner. The concentrations that were assessed are attainable in the urine of patients taking these agents orally.
Authors: Dragan J Golijanin; David Kakiashvili; Ralph R Madeb; Edward M Messing; Seth P Lerner Journal: World J Urol Date: 2006-11 Impact factor: 4.226
Authors: Kommula Dileep; Sowjanya Polepalli; Nishant Jain; Sudheer Kumar Buddana; R S Prakasham; M S R Murty Journal: Mol Divers Date: 2017-11-14 Impact factor: 2.943
Authors: Jean-Michel Michot; Marie F Heremans; Nancy E Caceres; Marie-Paule Mingeot-Leclercq; Paul M Tulkens; Françoise Van Bambeke Journal: Antimicrob Agents Chemother Date: 2006-05 Impact factor: 5.191
Authors: Tomasz Kloskowski; Sylwia Frąckowiak; Jan Adamowicz; Kamil Szeliski; Marta Rasmus; Tomasz Drewa; Marta Pokrywczyńska Journal: Front Oncol Date: 2022-06-08 Impact factor: 5.738
Authors: Elizabeth A Williamson; Leah Damiani; Andrei Leitao; Chelin Hu; Helen Hathaway; Tudor Oprea; Larry Sklar; Montaser Shaheen; Julie Bauman; Wei Wang; Jac A Nickoloff; Suk-Hee Lee; Robert Hromas Journal: Cancer Res Date: 2012-10-22 Impact factor: 12.701
Authors: Leonidas A Bourikas; George Kolios; Vassilis Valatas; George Notas; Ioannis Drygiannakis; Iordanis Pelagiadis; Pinelopi Manousou; Stefanos Klironomos; Ioannis A Mouzas; Elias Kouroumalis Journal: Br J Pharmacol Date: 2009-04-09 Impact factor: 8.739
Authors: Jakob Kljun; Anna K Bytzek; Wolfgang Kandioller; Caroline Bartel; Michael A Jakupec; Christian G Hartinger; Bernhard K Keppler; Iztok Turel Journal: Organometallics Date: 2011-04-06 Impact factor: 3.876
Authors: X Jiang; J E Castelao; S Groshen; V K Cortessis; D Shibata; D V Conti; J-M Yuan; M C Pike; M Gago-Dominguez Journal: Br J Cancer Date: 2009-01-27 Impact factor: 7.640